Sarepta Announces Q4 2024 Revenue Of $638.2M, Exceeding Guidance; ELEVIDYS Revenue At $384.2M; RNA PMO Revenue At $254M; FY24 Revenue Totals $1.79B; $1.5B In Cash And Investments At Year-End 2024; Reiterates 2025 Revenue Guidance Of $2.9B-$3.1B

Benzinga

Jan 14, 2025

– Preliminary total net product revenue of $638.2 million for the fourth quarter and $1.79 billion for full-year 2024, exceeding full-year guidance by over $100 million

– Preliminary ELEVIDYS net product revenue totaled $384.2 million for the fourth quarter, exceeding guidance by over $60 million, and $820.8 million for full-year 2024

– Preliminary RNA-based PMO net product revenue for the fourth quarter and full-year of 2024 totaled $254.0 million and $967.2 million, respectively

– Preliminary year-end 2024 cash, cash equivalents, restricted cash and investments balance of approximately $1.5 billion

– Reiterates 2025 full-year total net product revenue guidance of $2.9 to $3.1 billion

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported preliminary* fourth quarter and full-year 2024 net product revenue and cash on hand as of December 31, 2024, as part of its presentation today at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, Calif.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2503533239"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2503533239\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2503533239?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-14 01:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2503533239","market":"hk","top_or_hot":-1,"title":"Sarepta Announces Q4 2024 Revenue Of $638.2M, Exceeding Guidance; ELEVIDYS Revenue At $384.2M; RNA PMO Revenue At $254M; FY24 Revenue Totals $1.79B; $1.5B In Cash And Investments At Year-End 2024; Reiterates 2025 Revenue Guidance Of $2.9B-$3.1B","media":"Benzinga","content":"<html><body><p>– <i><strong>Preliminary total net product revenue of $638.2 million for the fourth quarter and $1.79 billion for full-year 2024, exceeding full-year guidance by over $100 million</strong></i></p><p>– <i><strong>Preliminary ELEVIDYS net product revenue totaled $384.2 million for the fourth quarter, exceeding guidance by over $60 million, and $820.8 million for full-year 2024</strong></i></p><p>– <i><strong>Preliminary RNA-based PMO net product revenue for the fourth quarter and full-year of 2024 totaled $254.0 million and $967.2 million, respectively</strong></i></p><p>– <i><strong>Preliminary year-end 2024 cash, cash equivalents, restricted cash and investments balance of approximately $1.5 billion</strong></i></p><p>– <i><strong>Reiterates 2025 full-year total net product revenue guidance of $2.9 to $3.1 billion</strong></i></p><p><a href=\"https://laohu8.com/S/SRPT\">Sarepta Therapeutics</a>, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported preliminary* fourth quarter and full-year 2024 net product revenue and cash on hand as of December 31, 2024, as part of its presentation today at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, Calif.</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sarepta Announces Q4 2024 Revenue Of $638.2M, Exceeding Guidance; ELEVIDYS Revenue At $384.2M; RNA PMO Revenue At $254M; FY24 Revenue Totals $1.79B; $1.5B In Cash And Investments At Year-End 2024; Reiterates 2025 Revenue Guidance Of $2.9B-$3.1B</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSarepta Announces Q4 2024 Revenue Of $638.2M, Exceeding Guidance; ELEVIDYS Revenue At $384.2M; RNA PMO Revenue At $254M; FY24 Revenue Totals $1.79B; $1.5B In Cash And Investments At Year-End 2024; Reiterates 2025 Revenue Guidance Of $2.9B-$3.1B\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2025-01-14 01:26</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>– <i><strong>Preliminary total net product revenue of $638.2 million for the fourth quarter and $1.79 billion for full-year 2024, exceeding full-year guidance by over $100 million</strong></i></p><p>– <i><strong>Preliminary ELEVIDYS net product revenue totaled $384.2 million for the fourth quarter, exceeding guidance by over $60 million, and $820.8 million for full-year 2024</strong></i></p><p>– <i><strong>Preliminary RNA-based PMO net product revenue for the fourth quarter and full-year of 2024 totaled $254.0 million and $967.2 million, respectively</strong></i></p><p>– <i><strong>Preliminary year-end 2024 cash, cash equivalents, restricted cash and investments balance of approximately $1.5 billion</strong></i></p><p>– <i><strong>Reiterates 2025 full-year total net product revenue guidance of $2.9 to $3.1 billion</strong></i></p><p><a href=\"https://laohu8.com/S/SRPT\">Sarepta Therapeutics</a>, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported preliminary* fourth quarter and full-year 2024 net product revenue and cash on hand as of December 31, 2024, as part of its presentation today at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, Calif.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SRPT","symbol_name":"Sarepta Therapeutics","start_time":0,"source_url":"https://www.benzinga.com/news/earnings/25/01/42954583/sarepta-announces-q4-2024-revenue-of-638-2m-exceeding-guidance-elevidys-revenue-at-384-2m-rna-pmo-r","article_id":"2503533239","we_media_id":"1052270027","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2503533239","pubTimestamp":1736789212,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Benzinga","introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"summary":"– Preliminary total net product revenue of $638.2 million for the fourth quarter and $1.79 billion for full-year 2024, exceeding full-year guidance by over $100 million– Preliminary ELEVIDYS net product revenue totaled","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"SRPT":"Sarepta Therapeutics","PMO":"普特南市政债券成长基金","RNA":"Avidity Biosciences, Inc."},"translate_title":"Sarepta宣布2024年第四季度收入为6.382亿美元，超出预期；ELEVIDYS收入为3.842亿美元；RNA PMO收入为2.54亿美元；2024财年收入总计$1.79 B；2024年底现金和投资$1.5 B；重申2025年收入指引为$2.9 B–$3.1 B","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RNA":1,"PMO":1,"SRPT":0.9},"content_text":"– Preliminary total net product revenue of $638.2 million for the fourth quarter and $1.79 billion for full-year 2024, exceeding full-year guidance by over $100 million– Preliminary ELEVIDYS net product revenue totaled $384.2 million for the fourth quarter, exceeding guidance by over $60 million, and $820.8 million for full-year 2024– Preliminary RNA-based PMO net product revenue for the fourth quarter and full-year of 2024 totaled $254.0 million and $967.2 million, respectively– Preliminary year-end 2024 cash, cash equivalents, restricted cash and investments balance of approximately $1.5 billion– Reiterates 2025 full-year total net product revenue guidance of $2.9 to $3.1 billionSarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported preliminary* fourth quarter and full-year 2024 net product revenue and cash on hand as of December 31, 2024, as part of its presentation today at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, Calif.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}